Acorda Therapeutics, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $117.6M | $118.6M | $129.1M | $153.0M | $192.4M | $106.2M |
| Operating income | −$265.0M | −$35.3M | −$79.0M | −$78.1M | −$311.6M | $38.5M |
| Net income | −$252.9M | −$65.9M | −$104.0M | −$99.6M | −$273.0M | −$8.2M |
| Total assets | $108.5M | $395.6M | $455.5M | $632.7M | $799.7M | $1.30B |
| Total liabilities | — | — | — | — | — | — |
| Equity | −$158.0M | $93.6M | $151.1M | $238.0M | $310.8M | $612.0M |
| EPS (diluted) | $-203.57 | $-65.23 | $-9.79 | $-12.32 | $-34.43 | $-0.18 |
| Shares out. | 24.3M | 13.3M | 9.5M | 48.0M | 47.6M | 46.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −225.2%
- Net margin
- −215.0%
- Return on equity
- 160.1%
- Return on assets
- −233.0%
- Return on capital (ROCE)
- —
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $-6.49
- Revenue growth (YoY)
- −0.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Accruals / assets
- −220.1%clean
- Piotroski F-Score
- 2/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 4 warning● 2 good- Negative shareholder equity
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Bankruptcy or receivership · Modified shareholder rights · Director / officer changeAug 9, 2024
- Regulation FD disclosureJul 23, 2024
- Completed an acquisition or dispositionJul 11, 2024
- Regulation FD disclosureJun 25, 2024
- Other material eventJun 12, 2024
- Other material eventJun 4, 2024
- Regulation FD disclosureMay 24, 2024
- Delisting / listing-standard noticeApr 26, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.